Compounded tirzepatide — the GLP-1/GIP dual agonist at the center of the weight-management category's fastest-growing segment — carries a monthly price tag ranging from $125 to $199 depending on the online provider, according to a new report from Ozari Health. The analysis, compiled from published prices across seven telehealth and compounding pharmacy platforms on October 19, 2026, is among the first systematic comparisons of consumer-facing costs in the compounded GLP-1 market.
The Price Gap
At the low end, a consumer on a short-term plan (three months or fewer) can access compounded tirzepatide for $125 per month; at the high end, the same plan window costs $199. Annualized, that spread widens considerably: twelve-month totals across the seven providers range from $1,500 to $2,587 — a $1,087 gap that the report attributes primarily to billing cycle structure, recurring membership or subscription fees, and how individual dose tiers are priced rather than to differences in the active pharmaceutical ingredient itself.
The report's framing matters for the functional foods and nutraceutical industry because compounded GLP-1 products have reshaped consumer expectations around weight management, appetite regulation, and metabolic health — categories where finished-formula supplement brands compete directly for wallet share. As branded tirzepatide (Zepbound/Mounjaro) has faced intermittent supply constraints, compounded versions produced by 503A and 503B pharmacies have captured a meaningful share of the GLP-1-adjacent consumer base, pulling spending away from traditional weight-management supplements and functional foods.
Market Context
For operators and formulators tracking the GLP-1 adjacency opportunity, pricing transparency in the compounded channel is a double-edged signal. On one hand, $125–$199 per month remains well below the out-of-pocket cost of branded injectable GLP-1 therapies, sustaining strong consumer demand. On the other, the compressed price range suggests competitive pressure is already intensifying among compounding platforms, which could accelerate consumer churn and shift attention back toward OTC functional alternatives — protein-enriched formats, satiety-focused fiber blends, and muscle-preservation supplements positioned for the "GLP-1 user" cohort.
Regulatory headwinds are a material variable. The FDA has signaled ongoing scrutiny of compounded tirzepatide's status under shortage-based compounding exemptions; any tightening of enforcement could rapidly reduce supply-side competition and push prices upward, further opening the addressable market for science-backed functional nutrition products targeting metabolic health, satiety, and body composition.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.
Frequently Asked Questions
What's the actual price range for compounded tirzepatide right now?
Compounded tirzepatide runs $125 to $199 per month across seven major telehealth and compounding pharmacy platforms, according to Ozari Health's October 2026 analysis. Over a twelve-month commitment, that spreads to $1,500–$2,587 — a $1,087 swing driven by subscription fees, billing cycles, and dose-tier pricing, not ingredient costs.
Why should supplement brands care about compounded GLP-1 pricing?
Compounded tirzepatide has directly cannibalized wallet share from traditional weight-management supplements and functional foods by resetting consumer expectations around efficacy for appetite regulation and metabolic health. Your finished-formula brands now compete head-to-head against injectable pharmaceuticals at $125–$199 monthly — a price point that changes category dynamics entirely.
Which providers are driving the price competition?
The Ozari Health report surveyed seven platforms but doesn't publicly rank them individually in the headline findings; however, the $74 monthly spread signals that some operators are absorbing membership fees while others front-load them into the per-dose cost. Request the full Ozari report to identify which players are pricing aggressively.
How much of the compounded tirzepatide market is real versus hype?
Supply constraints on branded Zepbound and Mounjaro have pushed real volume into 503A and 503B compounded channels — this is not speculative. The fact that seven platforms have published tirzepatite pricing at scale confirms the segment has moved beyond early adopters into mainstream telehealth distribution.
Does compounded tirzepatide pricing threaten my supplement SKU lineup?
Only if your weight-management or metabolic health claims compete directly on efficacy claims; if you're positioned as a complementary functional food or pre-GLP-1 solution, you have runway. But if you're in the core appetite-suppression or metabolic-acceleration space, $125–$199 monthly injectables now set the consumer's willingness-to-pay ceiling for oral alternatives.
